Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy
Date
1998
Authors
Nand, Swaran L.
Webster, Michael A.
Baber, Rodney J.
O'Connor, Vivienne
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Obstetrics and Gynecology, 1998; 91(5):678-684
Statement of Responsibility
Nand, Swaran L., Webster, Michael A., Baber, Rodney, O'Connor, Vivienne, for The Ogen/Provera Study Group
Conference Name
Abstract
Objective: To establish the optimum oral daily dose of micronized medroxyprogesterone acetate, given in combination with a fixed oral dose of estrone (E1) sulfate as hormone replacement therapy, that provides endometrial protection and induces cessation of vaginal bleeding.
Methods: This multicenter, randomized, double-blind study was conducted for 2 years. Five hundred sixty-eight postmenopausal women were randomized to take E1 sulfate 1.25 mg daily and one of three doses of medroxyprogester one acetate (2.5, 5, or 10 mg) daily. Any vaginal bleeding was recorded by patients in a daily diary, and endometrial biopsies were performed at entry into the study and at 3, 12, and 24 months.
Results: Forty-two percent of all women reported some bleeding at month 3 of therapy. However, by month 6, 76.5, 80.1, and 80.9% of women were amenorrheic in the 2.5-, 5-, and 10-mg medroxyprogesterone acetate groups, respec tively. Over time, the percentage of women with no bleeding increased in each group, and by 24 months 91.5, 89.9, and 94.3% were amenorrheic in the 2.5- and 10-mg medroxypro gesterone acetate groups, respectively. Approximately 10% of women continue to have some bleeding, regardless of the dose of medroxyprogesterone acetate. There were no statistically significant differences in the number of women with bleeding at any time point between the three groups. There were no cases of endometrial hyperplasia reported in the study population over the 2 years.
Conclusion: All three studied doses of medroxyprogester one acetate, given in combination with 1.25 mg of E1 sulfate, provide adequate endometrial protection and render approximately 80% of women amenorrheic by 6 months of therapy
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 1998 The American College of Obstetricians and Gynecologists